Low Co-Pays Drive Better Adherence to New Diabetes Drugs Low Co-Pays Drive Better Adherence to New Diabetes Drugs

Low co-pays linked with substantially better 12-month adherence to expensive SGLT2 inhibitors and GLP-1 agonists among US patients with type 2 diabetes or heart failure.Medscape Medical News
Source: Medscape Internal Medicine Headlines - Category: Internal Medicine Tags: Diabetes & Endocrinology News Source Type: news